α-Methylacyl coenzyme A racemase immunoreactivity in partial atrophy of the prostate

Brian P. Adley, Ximing J. Yang*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

It was reported that 15 of 19 consultation cases of prostatic partial atrophy were α-methylacyl coenzyme A racemase (AMACR)-positive. We investigated partial atrophy cases from a single institution using a standard AMACR immunostaining method. Immunohistochemical analysis was performed using an antibody cocktail containing p63, high-molecular-weight keratin (34βE12), and AMACR antibodies on 122 foci of partial atrophy. AMACR staining was analyzed in partial atrophy (n = 122) and compared with adjacent benign glands (n = 122) and prostatic carcinomas (n = 28). Of 122 foci of partial atrophy, 38 (31.1%) showed AMACR immunoreactivity. Typically, AMACR staining was weak or moderate. In addition, 82 (67.2%) showed patchy to negative distribution of basal cells. Partial atrophy may show AMACR immunoreactivity when using a 34βE12, p63, and AMACR antibody cocktail staining method. Compounding this problem, focal lack of basal cells may be seen. However, the AMACR staining pattern of partial atrophy is usually comparable to that of adjacent benign glands and substantially different from adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)849-855
Number of pages7
JournalAmerican journal of clinical pathology
Volume126
Issue number6
DOIs
StatePublished - Dec 2006

Keywords

  • AMACR
  • Partial atrophy
  • Prostate needle biopsy
  • α-Methylacyl coenzyme A racemase

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'α-Methylacyl coenzyme A racemase immunoreactivity in partial atrophy of the prostate'. Together they form a unique fingerprint.

Cite this